Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jun 28, 2013 5:57pm
26 Views
Post# 21580545

RE:ASSURE vs SATURN: Food For Thought

RE:ASSURE vs SATURN: Food For ThoughtSATURN trial only looked at IVUS effects after 2 years of treatment. There was no measurement made between the initial baseline IVUS scan and the post-2 year scan.

I don't think it is fair to say RVX-208 is acting too slow. I don't know of ANY orally available drug that has shown plaque regression in 6 months (including statins). So the only disappointment is that RVX-208 wasn't able to lay claim as the first drug to do this (I am not counting infusion therapies here.....I don't see these being a viable therapy for the masses).

Right now we can only guess how RVX-208 would behave in a 9-month, 12-month, or 24-month study. 


Bullboard Posts